Atara Biotherapeutics Book Value 2011-2026 | ATRA

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Atara Biotherapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-97.3 M	-99.2 M	127 M	280 M	462 M	291 M	339 M	178 M	254 M	315 M	103 M	-11 M	-3.73 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
462 M	-99.2 M	164 M

Quarterly Book Value Atara Biotherapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-36.6 M	-35 M	-55.1 M	-97.3 M	-90.5 M	-111 M	-98.3 M	-99.2 M	-50.8 M	7.45 M	65 M	127 M	187 M	257 M	224 M	280 M	310 M	332 M	399 M	462 M	462 M	462 M	462 M	291 M	291 M	291 M	291 M	339 M	339 M	339 M	339 M	178 M	178 M	178 M	178 M	254 M	254 M	254 M	254 M	315 M	315 M	315 M	315 M	103 M	103 M	103 M	103 M	50.1 M	50.1 M	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
462 M	-111 M	191 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
AbCellera Biologics ABCL	967 M	$ 3.55	-2.18 %	$ 1.06 B	Canada
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
ADMA Biologics ADMA	477 M	$ 15.66	-5.32 %	$ 3.73 B	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Aptorum Group Limited APM	11.8 M	$ 0.82	-0.73 %	$ 4.47 M	China
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
Apellis Pharmaceuticals APLS	370 M	$ 20.16	1.51 %	$ 2.54 B	USA
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
ANI Pharmaceuticals ANIP	429 M	$ 75.5	-1.35 %	$ 1.46 B	USA
Applied Therapeutics APLT	-17.1 M	-	-	$ 8.42 M	USA
Autolus Therapeutics plc AUTL	427 M	$ 1.48	-9.2 %	$ 378 M	Britain
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Corcept Therapeutics Incorporated CORT	648 M	$ 34.35	-3.75 %	$ 3.57 B	USA
Corbus Pharmaceuticals Holdings CRBP	-6.9 M	$ 7.8	-7.36 %	$ 33.8 M	USA
CorMedix CRMD	70.1 M	$ 6.32	-11.24 %	$ 322 M	USA
AVEO Pharmaceuticals AVEO	45.9 M	-	-	$ 521 M	USA
Champions Oncology CSBR	3.77 M	$ 5.79	-3.58 %	$ 79.1 M	USA
Axsome Therapeutics AXSM	88.3 M	$ 160.44	-2.22 %	$ 7.98 B	USA
BridgeBio Pharma BBIO	-2.08 B	$ 65.38	-1.74 %	$ 12.5 B	USA
Denali Therapeutics DNLI	1.23 B	$ 19.69	-3.34 %	$ 3.24 B	USA
Brainstorm Cell Therapeutics BCLI	-7.76 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	188 M	-	-4.8 %	$ 255 M	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
BeiGene, Ltd. BGNE	4.36 B	-	0.49 %	$ 251 B	Cayman-islands
Edesa Biotech EDSA	1.98 M	$ 3.8	-10.9 %	$ 12.2 M	USA
Equillium EQ	22.6 M	$ 1.79	2.0 %	$ 62.2 M	USA
Bellicum Pharmaceuticals BLCM	20.1 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	142 M	-	-7.31 %	$ 87 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Bellerophon Therapeutics BLPH	2.53 M	-	-74.18 %	$ 955 K	USA
BioLineRx Ltd. BLRX	13.5 M	$ 2.75	-2.14 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	6.09 B	$ 60.47	0.07 %	$ 11.6 B	USA
Eton Pharmaceuticals ETON	15.5 M	$ 17.04	-2.77 %	$ 437 M	USA